Randomized, Active-Comparison, Double-Blind, Phase 2 Study to Assess the Safety and Immunogenicity of Anthrax Vaccine Adsorbed (BioThrax) Without and With CPG 7909 Adjuvant (AV7909 Anthrax Vaccine), Using a Post-Exposure Prophylaxis Dosing Regimen in Adults 66 Years of Age or Older in Stable Health in Comparison to Adults 18-50 Years of Age in Stable Health
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Anthrax vaccine (Primary) ; Anthrax vaccine adsorbed adjuvanted Emergent BioSolutions (Primary) ; Agatolimod
- Indications Anthrax
- Focus Adverse reactions; Pharmacodynamics
- Acronyms B-SAFE
- 28 Oct 2020 Results assessing the capacity of anthrax vaccines to generate a protective immune response in adults 66 years of age or older, published in the Vaccine
- 13 Jul 2020 Status changed from active, no longer recruiting to completed.
- 16 Jan 2020 Planned End Date changed from 13 Dec 2019 to 31 May 2020.